Cooper Companies Inc (OQ:COO)

Business Focus: Glasses, Spectacles & Contact lenses

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 6101 Bollinger Canyon Road, Suite 500
SAN RAMON CA 94583
Tel: 1-925-4603663
Website: https://www.coopercos.com
IR: See website
<
Key People
Albert G. White
President, Chief Executive Officer, Director
William A. Kozy
Vice Chairman of the Board, Lead Independent Director
Brian George Andrews
Chief Financial Officer, Executive Vice President, Treasurer
Holly R. Sheffield
President - CooperSurgical, Inc
Gerard H. Warner
President, CooperVision, Inc
Daniel G. McBride
Chief Operating Officer, Executive Vice President
Agostino Ricupati
Senior Vice President - Finance and Tax, Chief Accounting Officer
Nicholas S. Khadder
Vice President, General Counsel, Company Secretary
 
Business Overview
The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision and CooperSurgical. CooperVision is engaged in the contact lens industry. CooperVision's products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys, Biofinity toric & Biofinity XR toric, Biofinity multifocal, Biofinity toric multifocal, clariti 1 day, clariti 1 day toric, clariti 1 day multifocal, MiSight 1 day, Avaira Vitality and Avaira Vitality toric. CooperSurgical is a fertility and women's health company dedicated to assisting women, babies and families around the world. CooperSurgical provides a range of products and services with an emphasis on improving fertility solutions, empowering office-based care, and advancing hospital care within women's health. CooperSurgical's brands include Paragard, ER-Complete, Fetal Pillow, INSORB, PGT-Complete, RUMI II and others.
Financial Overview
For the three months ended 31 January 2024, Cooper Companies Inc revenues increased 9% to $931.6M. Net income decreased 4% to $81.2M. Revenues reflect CooperVision segment increase of 7% to $621.5M, CooperSurgical segment increase of 12% to $310.1M, United States segment increase of 8% to $470.4M, Europe segment increase of 11% to $276.6M, Rest of the World segment increase of 5% to $184.6M.
Employees: 15,000 as of Oct 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $20,859M as of Jan 31, 2024
Annual revenue (TTM): $3,666M as of Jan 31, 2024
EBITDA (TTM): $956.50M as of Jan 31, 2024
Net annual income (TTM): $290.80M as of Jan 31, 2024
Free cash flow (TTM): $134.50M as of Jan 31, 2024
Net Debt Last Fiscal Year: $2,637M as of Jan 31, 2024
Shares outstanding: 198,756,284 as of Feb 23, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.